Corporate Logo(source: daewoong.co.kr)
On July 3,Korea Investment & Securities Co.,Ltd raised its target price for Daewoong Pharmaceutical (069620) by 14%, citing expectations of strong second-quarter earnings driven by increased sales of botulinum toxin products.
Analyst Hae Joo Wi estimated Daewoong Pharmaceutical’s second-quarter standalone revenue at 343.2 billion won and operating profit at 57.8 billion won, representing year-on-year increases of 5% and 17%, respectively.
Wi attributed the anticipated strong performance to a surge in sales of botulinum toxin products supplied to Evolus, the company’s U.S. partner.
Based on second-quarter export data from domestic firms, Wi noted that “botulinum toxin exports to the U.S. rose 27% year-on-year and 40% quarter-on-quarter, and Daewoong Pharmaceutical likely accounted for a significant portion of that growth.”
He added, “Boosted by increased shipments to Evolus, the company is expected to achieve an operating margin of approximately 17% for the first time in its history.” He also highlighted that Daewoong is making solid progress in delivering on its commitments to grow revenue from new drugs and improve gross margin.
Korea Investment & Securities maintained its “Buy” rating and raised the target price from 220,000 won to 250,000 won.
*[KOSPI]Daewoong Pharmaceutical(069620) is engaged in the manufacture and sale of pharmaceuticals, with key products including Ursa, Albis, Olmetec, Impactamin, and Nexium, among others. Its market capitalization is 1.68 trillion won(as of July 2, 2025, closing price).
Corporate Logo(source: daewoong.co.kr)
On July 3,Korea Investment & Securities Co.,Ltd raised its target price for Daewoong Pharmaceutical (069620) by 14%, citing expectations of strong second-quarter earnings driven by increased sales of botulinum toxin products.
Analyst Hae Joo Wi estimated Daewoong Pharmaceutical’s second-quarter standalone revenue at 343.2 billion won and operating profit at 57.8 billion won, representing year-on-year increases of 5% and 17%, respectively.
Wi attributed the anticipated strong performance to a surge in sales of botulinum toxin products supplied to Evolus, the company’s U.S. partner.
Based on second-quarter export data from domestic firms, Wi noted that “botulinum toxin exports to the U.S. rose 27% year-on-year and 40% quarter-on-quarter, and Daewoong Pharmaceutical likely accounted for a significant portion of that growth.”
He added, “Boosted by increased shipments to Evolus, the company is expected to achieve an operating margin of approximately 17% for the first time in its history.” He also highlighted that Daewoong is making solid progress in delivering on its commitments to grow revenue from new drugs and improve gross margin.
Korea Investment & Securities maintained its “Buy” rating and raised the target price from 220,000 won to 250,000 won.
*[KOSPI]Daewoong Pharmaceutical(069620) is engaged in the manufacture and sale of pharmaceuticals, with key products including Ursa, Albis, Olmetec, Impactamin, and Nexium, among others. Its market capitalization is 1.68 trillion won(as of July 2, 2025, closing price).